Results 91 to 100 of about 169,027 (313)
Advanced Science, EarlyView.In the TME of NPC, C1q secreted by C1q+ TAMs interacted with GPR17 to activate PI3K/AKT signaling through strengthening GPR17 coupling PI3K and increasing calcium levels in tumor cells. The activated PI3K/AKT signaling further induces DNA hypermethylation to promote the malignancy and stemness of tumor cells.
Yunzhi Liu +11 more
wiley +1 more source
Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches [PDF]
, 2013 Altered networks of gene regulation underlie many pathologies, including cancer. There are several proteins in cancer cells that are turned either on or off, which dramatically alters the metabolism and the overall activity of the cell, with the complex ...
Daniotti, Jose Luis +4 more
core +2 more sources
Therapeutic Advances in Neurological DisordersInebilizumab is one of the monoclonal antibodies approved as maintenance therapy for aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder (NMOSD).
Xuefen Chen +3 more
doaj +1 more source
Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]
, 2017 INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K. +2 more
core +2 more sources
Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis [PDF]
, 2020 Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic
Foerster, John, Molęda, Aleksandra
core +2 more sources
Dupilumab for recalcitrant prurigo nodularis: Case report
Revista da Sociedade Portuguesa de Dermatologia e Venereologia, 2022 Dupilumab is a recombinant fully human monoclonal antibody modulating the signaling of the interleukin (IL)—4 and IL-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis.
Joel Reis, Inês Raposo, Manuela Selores
doaj
In Silico Trial to test COVID-19 candidate vaccines: a case study with UISS platform [PDF]
arXiv, 2020 SARS-CoV-2 is a severe respiratory infection that infects humans. Its outburst entitled it as a pandemic emergence. To get a grip on this, outbreak specific preventive and therapeutic interventions are urgently needed. It must be said that, until now, there are no existing vaccines for coronaviruses.
arxiv
Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies [PDF]
arXiv, 2023 Alzheimer's disease (AD) is a prevalent, progressive, and ultimately fatal neurodegenerative disorder that is defined pathologically by the accumulation of amyloid plaques and tau neurofibrillary tangles in the brain. There remains an unmet need for therapies that can halt or slow the course of AD. To address this need, the FDA has provided a mechanism,
arxiv
An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA. [PDF]
, 2015 Antibody-mediated rejection (AMR) of solid organ transplants (SOT) is characterized by damage triggered by donor-specific antibodies (DSA) binding donor Class I and II HLA (HLA-I and HLA-II) expressed on endothelial cells.
Fishbein, MC +7 more
core +1 more source
TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
American Journal of Hematology, EarlyView.ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah +2 more
wiley +1 more source